Loading...
Limited evidence from the 1990s suggests that whole blood or serum from patients who have survived Ebola virus disease (EVD) might be an effective adjunctive therapy to reduce EVD-related mortality. To further explore this possibility, researchers enrolled symptomatic patients with laboratory-confirmed EVD in a nonrandomized trial at an Ebola treatment unit (ETU) in Guinea.
Participants received two consecutive infusions of ABO-compatible convalescent plasma (obtained from separate convalescent donors) on the day of EVD diagnosis or up to 2 days later. A historical-control group, seen at the same ETU during the previous 5 months, received only standard EVD treatment. Upon diagnosis, blood samples from both groups were screened for Ebola viru…